GT Biopharma Status update

Thank you, Michael. We're delighted to be here and very excited to present some information on our company.

Great. Give me one second here to click the right buttons.

Sure. Take your time. Is that the correct screen?

Okay, great. Okay. Thanks, everybody. I am delighted to be here. Just a little bit of an introduction on myself. As mentioned, I am a consultant for GT Biopharma. I am also a physician, and my job is really to take care of patients with cancer, which has been my motivation to focus my efforts on NK cell therapy for the past 30 years. I am going to take you through some of the journey about how we got there. There are some just very big highlighting things that I wanted to start off with. I think it is very clear that things have been changing in medical oncology. We started off with chemotherapy and radiation therapy, and I think what is going to derive the future of cancer therapy is something called immunotherapy, ways to stimulate the immune system to be very specific for that cancer cell.

I think all of us have friends, family, hopefully not yourselves, that have had cancer and have gone through chemotherapy, which not only targets the tumor, but also has many, many side effects of normal tissues. I think what we are trying to do overall on our platform that I am going to cover today is just some very basic steps about how to specifically target the immune system to the cancer cell while not having any of the side effects that one might see with chemotherapy or radiation therapy. There are a number of engagers that have been out here. I am not going to go through all of these. This has been a big market driver in a lot of different fields, and I will go through the specifics as I go through the discussion. Michael, should I continue on, or do you have further questions for me now?

Sounds great. Okay, thanks. I wanted to start off, one of our first forays into the clinic is a molecule called GTB-3550, and this is a molecule that was designed to target CD33, which is present on AML cells in MDS, which is myelodysplastic syndrome. We treated a number of different patients, and this is really taking you into a background of where we are today. The therapy was given as a continuous infusion in 96-hour blocks for three weeks in a row, and this was followed by a weekend off after each block of therapy. We went through six individual dose cohorts. There were two patients in each of these cohorts, and I wanted to take you through a very exciting summary of what we found in this early study that was completed a couple of years ago.

The first thing is, this is the number of activated NK cells circulating in one's blood. When the NK cell infusion was on, remember, this is a 96-hour infusion, so day 3, day 10, and day 17 is the Wednesday while the infusion was going. You see all these cells at these peak areas get very highly activated. When you look on the Monday after the next infusion cycle, you see that this is followed by a period of rest. This gives you this seesaw pattern that you see on this graph. The most important thing to me as an NK cell biologist is what did we do with the NK cells circulating in the blood? That's represented by this right panel. You could see, again, when the infusion is on at day 3, day 10, and day 17, cells get activated.

They get pushed out of the blood into tissue, which is where we want them to be. Then again, on day 8, after the first cycle of therapy, after the second cycle, or after the third cycle, you see this tremendous dose-dependent expansion of NK cells in the peripheral blood. Here we're trying to increase the immune cells that we think will be targeting to the cancers. This has been very exciting to us.